Relapsed/Refractory B-cell Malignancies
Conditions
Keywords
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL, Waldenström Macroglobulinemia (WM), Non-Hodgkin Lymphoma (NHL), Bruton's tyrosine kinase-BTK, BTK Degrader, AC676, AC0676
Brief summary
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokinetics of AC676 * Evaluate the effectiveness of AC676
Detailed description
AC676-001 is a Phase I, first-in-human, open-label, multi-center dose-escalation study of AC676 given as a single agent. AC676 is an investigational medicinal product that is an orally bioavailable BTK degrader for the treatment of B-cell malignancies.
Interventions
DRUGAC676
AC676 will be given orally (PO) on a 28-day cycle.
Sponsors
Accutar Biotechnology Inc
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult male and female patients, at least 18 years-of-age at the time of signature of the informed consent form (ICF). 2. Patients with histologically confirmed relapsed/refractory Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), non-GCB Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), or Waldenström Macroglobulinemia (WM). 3. Must have received at least 2 prior systemic therapies or have no other therapies to provide significant clinical benefit in the opinion of the Investigator or who are not amenable (intolerability, patient choice) to standard therapies.
Exclusion criteria
Patients who meet any of the following criteria will be excluded from study entry: 1. Treatment with any of the following: * Small molecule anti-cancer drugs within 5 half-lives or 2 days (whichever is longer, not to exceed 14 days). * Systemic chemotherapy within 14 days. * Radiation therapy within 14 days * Biologics (Antibodies) treatment within 28 days, * Radioimmunoconjugates or toxin conjugates within 12 weeks. * Prior Chimeric antigen receptor (CAR) T cell therapy (and prior use of immunoglobulin replacement therapy to treat associated adverse events) within 3 months. For patients with DLBCL, no prior CAR- T therapy is allowed. * Autologous or allogenic stem cell transplant within 100 days and must not have ongoing graft-versus-host disease (GVHD) and no ongoing therapy to treat GVHD. 2. History of central nervous system lymphoma/leukemia in remission for less than 2 years. 3. Medical history of active bleeding within 2 months prior to study entry, or susceptible to bleeding by the judgement of investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of dose limiting toxicities (DLTs) from AC676 monotherapy | From cycle 1 day 1 to Cycle 1 day 28. Cycles are 28 days. |
| Incidence of treatment-emergent adverse events (TEAEs) and clinically significant Grade 3 or higher laboratory abnormalities using CTCAE v5.0 criteria. | Approximately 18 months |
| Maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) | Approximately 18 months |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetic Analysis: time to maximum plasma concentration (tmax) | Up to approximately 20 weeks |
| Pharmacokinetic Analysis: terminal elimination half-life (t1/2) | Up to approximately 20 weeks |
| Objective Response Rate (ORR) in patients receiving AC676 | Approximately 18 months |
| Pharmacokinetic Analysis: area under the plasma concentration-time curve over the dosing interval (AUC(0-inf)) | Up to approximately 20 weeks |
| Time to Response (TTR) in patients receiving AC676 | Approximately 18 months |
| Disease Control Rate (DCR) in patients receiving AC676 | Approximately 18 months |
| Progression Free Survival rate (PFS) in patients receiving AC676 | Approximately 18 months |
| Duration of Response (DOR) in patients receiving AC676 | Approximately 18 months |
| Pharmacokinetic Analysis: area under the plasma concentration-time curve from over the dosing interval (AUC(0-tau)) | Up to approximately 20 weeks |
| Pharmacokinetic Analysis: maximum plasma concentration (Cmax) | Up to approximately 20 weeks |
Countries
United States
Contacts
Primary ContactAccutar Biotechnology
Outcome results
None listed